Trusted advisors with deep expertise

Steven Devine, MD is Associate Scientific Director/Senior Vice President of Research at the Center for International Blood and Marrow Transplant Research (CIBMTR), a research collaboration between the National Marrow Donor Program, also known as Be The Match, and the Medical College of Wisconsin. Steven is a board-certified oncologist and was the Director of the Blood and Marrow Transplant Program at Ohio State University Hospital in Columbus. Prior to that, he held positions at Washington University in St. Louis, the University of Illinois in Chicago, and Emory University in Atlanta. He also served on the graft-versus-host disease advisory boards of Bristol-Myers Squibb and Incyte Pharmaceuticals, the Kiadis advisory board and the Genzyme advisory board.

Steven is immediate Past-Chair of the National Heart Lung and Blood Institute/NCI-sponsored Blood and Marrow Transplant Clinical Trials Network. He has also served as a member of the Board of Directors of the National Cancer Institute (NCI) Alliance for Clinical Trials and the American Society of Blood and Marrow Transplantation.

Steven received his MD from the University of Massachusetts and completed his internship and residency at Michael Reese Hospital in Chicago. He then went on to complete a clinical fellowship of hematology and oncology at the University of Chicago and completed his fellowship in bone marrow transplant at Emory University.

The research of Hans-Peter Kiem, MD, PhD has focused on stem cell and transplantation biology, cell and gene therapy, and the development and use of novel gene-editing technologies. The overall goal has been the development of improved treatment approaches for patients with genetic and infectious diseases and cancer, in particular, hematologic malignancies. He is a clinically active hematologist/oncologist seeing patients on the marrow transplant, immunotherapy, and MDS/AML service. Hans-Peter has extensive experience training students and postdoctoral fellows and has mentored more than 50 trainees in his lab over the past 20 years. Many of his trainees now hold tenured faculty positions in the U.S. and Germany. Hans-Peter has been the Sponsor of four clinical gene therapy studies (HIV, glioblastoma, and Fanconi anemia) and he is the PI or Co-PI of many R01 or Program Project grants. Hans-Peter has also served on the NIH Recombinant DNA Advisory Committee (RAC) for five years, the last year as Chair, and served as the Chair of the Stem Cell Committees for both the American Society for Gene and Cell Therapy (ASGCT) and the American Society of Hematology.

Hans-Peter received his MD and PhD degrees from the University of Ulm in Germany and then joined Dr. Karl Blume’s research group at Stanford University as a research fellow, working with Drs. Sklar and Cleary to study molecular abnormalities and minimal residual in patients with lymphoma (Oncogene 1990; Blood 1991) and with Drs. Weissman and Negrin on the use of a novel immunodeficient mouse model for lymphoma (J. Exp. Med. 1991). After a two-year fellowship at Stanford, Hans-Peter went on to complete his residency in Internal Medicine and his Physician/Scientist training at Vanderbilt University. He joined the Fred Hutchinson Cancer Research Center in 1992, where he completed his clinical fellowship in Oncology.

Rob Soiffer, MD is currently Chief of the Division of Hematologic Malignancies and Co-Director of the Adult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute. He joined Dana-Farber in 1988 after completing a medical oncology fellowship also at Dana-Farber. Rob is Chairman of the Center for International Blood and Marrow Transplant Research advisory committee and has served as Vice President (2006), President (2007), and immediate Past President (2008) of the American Society of Blood and Marrow Transplantation. Rob graduated from New York University School of Medicine in 1983 and trained in internal medicine at Brigham and Women’s Hospital, where he also was chief medical resident.

Eric Sievers, MD, is currently Chief Medical Officer at BioAtla, Inc. Eric has over 25 years of clinical and translational biomedical research experience in multiple settings, including biotechnology industry, hospital- and clinic-based clinical practice and academics. During his nine years at Seattle Genetics, he was closely involved with the development and regulatory approval of ADCETRIS (brentuximab vedotin), an ADC. Serving in multiple roles of increasing leadership responsibility, he led the Seattle Genetics clinical team and Takeda (Millennium) development partner to design, initiate and enroll four randomized Phase 3 registration trials for ADCETRIS that each ultimately resulted in new indications approved by the FDA. Eric has managed clinical development efforts from Phase 1 to Phase 3 clinical trials, from strategy planning to study execution and BLA/NDA submissions. Prior to his career at Seattle Genetics, Eric was Medical Director at ZymoGenetics where he designed and supervised clinical trials of recombinant human interleukin 21 and TACI-Fc5 for patients with cancer and evaluated new oncology opportunities.  Before then, he was with the Fred Hutchinson Cancer Research Center for 12 years where he attained the position of Assistant Member and was Assistant Professor of Pediatrics at the University of Washington. During this time, he served as the lead investigator of Phase 1 and pivotal trials that resulted in the approval of an antibody drug conjugate MYLOTARG© indicated for patients with acute myeloid leukemia. Eric’s most recent position was Chief Medical Officer at Trillium Therapeutics where he developed clinical trial strategies and oversaw all clinical development employing a decoy receptor to block the CD47 “do not eat” signal overexpressed by cancer cells. Eric received both his medical degree and his B.A. degree from Brown University.

Yi-Bin Chen, MD is the Director of the Hematopoietic Cell Transplant and Cell Therapy Program at Massachusetts General Hospital. Yi-Bin is the inaugural Allan Rogers, Jr. and Cara J. Rogers Endowed Chair and an Associate Professor at Harvard Medical School. He has spent his career in clinical investigation with the goal of improving outcomes for patients undergoing hematopoietic cell transplantation. Yi-Bin has led early pilot and Phase 1 efforts through pivotal international Phase 3 trials in almost all aspects of transplantation. Most recently, he has focused on novel agents for the prevention and treatment of graft-vs-host disease (GVHD) as well as the incorporation of maintenance therapies after transplantation to prevent disease relapse.